Regeneron’s Inmazeb drug receives FDA approval for treating Ebola virus
Category: #headlines  | By Nikita Chaurasia  | Date: 2020-10-16 |
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Regeneron’s Inmazeb drug receives FDA approval for treating Ebola virus

According to reliable sources, New York-headquartered biotechnology company, Regeneron Pharmaceuticals Inc. has recently made it to the headlines after its patented Inmazeb drug received approval from the U.S. FDA (Food & Drug Administration) for the treatment of the Ebola virus.

For the record, Inmazeb is a mixture of three monoclonal antibodies, namely maftivimab, atoltivimab, and odesivimab-ebgn. The drug stops the spread of Ebola virus by inhibiting glycoprotein present on the surface of this virus. The antibodies present in it can bind to this glycoprotein and block attachment and virus invasion into healthy cells.

Reportedly, Inmazeb was initially evaluated in a clinical trial round called the PALM trial, that included over 382 individuals infected with the Ebola virus. The trial round was conducted amidst the Ebola virus outbreak between 2018 and 2019 and was led by the Institut National de Recherche Biomédicale along with the U.S. National Institutes of Health.

It is to be noted that the initial symptoms observed after the dosage of Inmazeb included vomiting, tachypnea, tachycardia, chills, and fever. In this context, Regeneron was reported stating that the treatment can give rise to infusion-related events such as hypersensitivity and subsequently discontinued the trial.

However, a recent study by Regeneron revealed that the treatment of patients with Ebola virus using Inmazeb revealed a primary efficacy end point of over 28-day mortality. Additionally, 51% of the 154 patients involved in the study showed rapid recovery.

Regeneron Pharmaceuticals Inc. is reportedly working on the development of REGN-COV2, a drug aimed at the treatment of the COVID-19 virus.

In other news, American multinational pharmaceutical company, Pfizer Inc. has reportedly received provisional determination from the Australian regulatory body, TGA (Therapeutic Goods Administration) for its COVID-19 vaccine, mRNA (messenger ribonucleic acid).

Source credits:

Reference link: https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-ebola-virus

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia     twitter

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More..

More News By Nikita Chaurasia

Dr. Reddy’s becomes India’s second biggest drugmaker by sales

Dr. Reddy’s becomes India’s second biggest drugmaker by sales

By Nikita Chaurasia

Dr. Reddy's Laboratories Ltd. and Cipla Ltd. surpassed Aurobindo Pharma to rank as the 2nd and 3rd largest drug manufacturers in India by sales in the three months that ended on September 30. This was the first change in the pecking order of the ...

UK’s business confidence drops to its lowest point since 2009

UK’s business confidence drops to its lowest point since 2009

By Nikita Chaurasia

According to recent data, business confidence in the UK dropped to 18% in October, which was its lowest level in at least 13 years. In contrast, however, net balances of confidence stood at 28% in June and 56% in February, according to Accenture and ...

Attero aims to increase recycling capacity, plans for IPO in 2025

Attero aims to increase recycling capacity, plans for IPO in 2025

By Nikita Chaurasia

Attero Recycling, a firm that recycles electronic waste, is aiming to launch an initial public offering (IPO) in 2025, according to its Co-Founder and CEO Nitin Gupta. As per Gupta, the company is currently debating whether to list its shares in I...